$435 Million is the total value of Sarissa Capital Management LP's 16 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 5.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARIA | ARIAD PHARMACEUTICALS INC | $106,270,000 | +0.4% | 12,850,000 | 0.0% | 24.46% | +9.5% | |
| ABBV | ABBVIE INC. | $106,160,000 | +14.8% | 1,580,000 | 0.0% | 24.43% | +25.2% | |
| DGX | Sell | QUEST DIAGNOSTICS INC | $41,699,000 | -30.0% | 575,000 | -25.8% | 9.60% | -23.6% |
| MDCO | Buy | MEDICINES CO | $38,964,000 | +14.4% | 1,361,900 | +12.1% | 8.97% | +24.8% |
| AEGR | Buy | AEGERION PHARMACEUTICALS INC | $38,639,000 | -9.8% | 2,036,829 | +24.4% | 8.89% | -1.6% |
| AMGN | Sell | AMGEN INC | $30,704,000 | -39.6% | 200,000 | -37.1% | 7.07% | -34.1% |
| MRK | MERCK & CO INC NEW | $22,772,000 | -1.0% | 400,000 | 0.0% | 5.24% | +8.0% | |
| ITCI | INTRA CELLULAR THERAPIES INC | $11,502,000 | +33.8% | 360,000 | 0.0% | 2.65% | +46.0% | |
| APRI | APRICUS BIOSCIENCES INC | $11,157,000 | -8.6% | 6,524,505 | 0.0% | 2.57% | -0.3% | |
| RPRX | REPROS THERAPEUTICS INC | $8,096,000 | -16.8% | 1,132,367 | 0.0% | 1.86% | -9.2% | |
| VVUS | VIVUS INC | $6,075,000 | -4.1% | 2,573,943 | 0.0% | 1.40% | +4.6% | |
| KIN | KINDRED BIOSCIENCES INC | $4,700,000 | -4.5% | 689,091 | 0.0% | 1.08% | +4.2% | |
| AVEO | Sell | AVEO PHARMACEUTICALS INC | $4,026,000 | +8.0% | 2,313,759 | -10.0% | 0.93% | +17.8% |
| ANIP | ANI PHARMACEUTICALS INC | $1,924,000 | -0.8% | 31,000 | 0.0% | 0.44% | +8.3% | |
| TRGT | TARGACEPT INC | $1,758,000 | -6.0% | 630,000 | 0.0% | 0.40% | +2.5% | |
| EBIO | ELEVEN BIOTHERAPEUTICS INC. | $116,000 | -68.5% | 41,200 | 0.0% | 0.03% | -65.4% | |
| FLML | Exit | FLAMEL TECHNOLOGIES SAsponsored adr | $0 | – | -875,000 | -100.0% | -3.32% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.